Comparison Of Zotarolimus-eluting Stents Versus Sirolimus-eluting Stents Versus Paclitaxel-eluting Stents For Primary Percutaneous Coronary Intervention:a Systematic Review

Objective To compare the efficacy and safety of paclitaxel eluting stent, sirolimus eluting stent, and zotarolimus eluting stent in primary percutaneous coronary(PCI) intervention for acute ST-segment elevation myocardial infarction(STEMl). Methods We search the PubMed, EMbase, Cochrane Library, EBSCO, Springer, Ovid, VIP, Wanfang Data, CNKI, and CBM for clincical controlled trials on the use of three stents in PCI for STEMI (up to April2012). We screen the articles we searched according to the exclusion criteria and inclusion criteria. The quality of included trials was evaluated according the Cochrane handbook5.1.0. Revman5.0software was used for data analysis. Results There are there article involving1219patients which are included in our study. The result of Meta analysis showed that there is no significant difference of primary end point (MACE and thrombosis) among the three stents in PCI for STEMI at12months. An article reported the insegment late loss (0.46±0.48mm,0.47±0.50mm,0.28±0.42mm, P=0.029) and the restenosis rate (15.9%,12.3%,2.7%, P=0.027) at8months. Another article reported the insegment late loss (0.79±0.67mm,0.51±0.55mm,0.34±0.39mm, P<0.001) and the restenosis rate (14.0%,4.4%,1.7%, P=1.000) at9months. Conclusion There is no significant difference of safety among the three stents in PCI for STEMI. but compared to ZES and PES, the SES is the most effective stent in PCI for STEMI.